Literature DB >> 27141344

Targeted immunotherapy for pediatric solid tumors.

Lisa M Kopp1, Emmanuel Katsanis1.   

Abstract

Metastatic and refractory pediatric solid tumor malignancies continue to have a poor outcome despite the > 80% cure rates appreciated in many pediatric cancers. Targeted immunotherapy is impacting treatment and survival in these aggressive tumors. We review current promising immunotherapeutic approaches in the pediatric oncology solid tumor setting.

Entities:  

Keywords:  Immunotherapy; pediatric oncology; solid tumors

Year:  2015        PMID： 27141344      PMCID： PMC4839383          DOI： 10.1080/2162402X.2015.1087637

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  79 in total

1.  Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Authors:  Suzanne Shusterman; Wendy B London; Stephen D Gillies; Jacquelyn A Hank; Stephan D Voss; Robert C Seeger; C Patrick Reynolds; Jennifer Kimball; Mark R Albertini; Barrett Wagner; Jacek Gan; Jens Eickhoff; Kenneth B DeSantes; Susan L Cohn; Toby Hecht; Brian Gadbaw; Ralph A Reisfeld; John M Maris; Paul M Sondel
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair.

Authors:  Bing Li; Ana P Castano; Thomas E Hudson; Brian T Nowlin; Shuei-Liong Lin; Joseph V Bonventre; Kenneth D Swanson; Jeremy S Duffield
Journal:  FASEB J       Date:  2010-08-13       Impact factor: 5.191

Review 3.  Advances in chimeric antigen receptor immunotherapy for neuroblastoma.

Authors:  Andras Heczey; Chrystal U Louis
Journal:  Discov Med       Date:  2013-12       Impact factor: 2.970

4.  WT1 peptide immunotherapy for cancer in children and young adults.

Authors:  Yoshiko Hashii; Emiko Sato; Hideaki Ohta; Yoshihiro Oka; Haruo Sugiyama; Keiichi Ozono
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

5.  Expression of Wilms tumor 1 gene in a variety of pediatric tumors.

Authors:  Takaharu Oue; Shuichiro Uehara; Hiroaki Yamanaka; Yuichi Takama; Yusuke Oji; Masahiro Fukuzawa
Journal:  J Pediatr Surg       Date:  2011-12       Impact factor: 2.545

6.  Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.

Authors:  Timothy P Cripe; Minhtran C Ngo; James I Geller; Chrystal U Louis; Mark A Currier; John M Racadio; Alexander J Towbin; Cliona M Rooney; Adina Pelusio; Anne Moon; Tae-Ho Hwang; James M Burke; John C Bell; David H Kirn; Caroline J Breitbach
Journal:  Mol Ther       Date:  2014-12-22       Impact factor: 11.454

Review 7.  Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.

Authors:  Mahiuddin Ahmed; Nai-Kong V Cheung
Journal:  FEBS Lett       Date:  2013-12-01       Impact factor: 4.124

8.  Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors.

Authors:  Aiko Suminoe; Akinobu Matsuzaki; Hiroyoshi Hattori; Yuhki Koga; Toshiro Hara
Journal:  Pediatr Transplant       Date:  2008-11-01

9.  Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma.

Authors:  Vincent I Poon; Michael Roth; Sajida Piperdi; David Geller; Jonathan Gill; Erin R Rudzinski; Douglas S Hawkins; Richard Gorlick
Journal:  Clin Sarcoma Res       Date:  2015-01-24

10.  Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).

Authors:  Samuel Q Li; Adam T Cheuk; Jack F Shern; Young K Song; Laura Hurd; Hongling Liao; Jun S Wei; Javed Khan
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240
View more
  6 in total

1.  Treatment and outcome of adult-onset neuroblastoma.

Authors:  Maya Suzuki; Brian H Kushner; Kim Kramer; Ellen M Basu; Stephen S Roberts; William J Hammond; Michael P LaQuaglia; Suzanne L Wolden; Nai-Kong V Cheung; Shakeel Modak
Journal:  Int J Cancer       Date:  2018-04-06       Impact factor: 7.396

2.  Nutritional status and clinical outcomes in pediatric patients with solid tumors : A systematic review of the literature.

Authors:  Lenat Joffe; Sarah Dwyer; Julia L Glade Bender; A Lindsay Frazier; Elena J Ladas
Journal:  Semin Oncol       Date:  2018-12-21       Impact factor: 4.929

3.  Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.

Authors:  Tsung-Yi Lin; Jeong A Park; Alan Long; Hong-Fen Guo; Nai-Kong V Cheung
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 12.469

4.  Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.

Authors:  Nobuhiro Tsuchiya; Ako Hosono; Toshiaki Yoshikawa; Kayoko Shoda; Kazuto Nosaka; Manami Shimomura; Junichi Hara; Chika Nitani; Atsushi Manabe; Hiroki Yoshihara; Yosuke Hosoya; Hide Kaneda; Yoshiaki Kinoshita; Kenichi Kohashi; Kenichi Yoshimura; Norihiro Fujinami; Keigo Saito; Shoichi Mizuno; Tetsuya Nakatsura
Journal:  Oncoimmunology       Date:  2017-09-27       Impact factor: 8.110

5.  Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial.

Authors:  Yu Akazawa; Ako Hosono; Toshiaki Yoshikawa; Hide Kaneda; Chika Nitani; Junichi Hara; Yoshiaki Kinoshita; Kenichi Kohashi; Atsushi Manabe; Miki Fukutani; Masashi Wakabayashi; Akihiro Sato; Kayoko Shoda; Manami Shimomura; Shoichi Mizuno; Yasunari Nakamoto; Tetsuya Nakatsura
Journal:  Cancer Sci       Date:  2019-11-19       Impact factor: 6.716

Review 6.  Immunotherapy Associated Neurotoxicity in Pediatric Oncology.

Authors:  Haneen Shalabi; Anandani Nellan; Nirali N Shah; Juliane Gust
Journal:  Front Oncol       Date:  2022-02-21       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.